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OBJECTIVE: To evaluate ipsilateral breast tumor recurrence after breast-conserving surgery for locally advanced
breast cancer.
METHODS: A retrospective observational cohort study was performed in patients with locally advanced breast
cancer submitted to breast-conserving surgery after neoadjuvant chemotherapy based on an adriamycin-
cyclophosphamide-paclitaxel regimen. We evaluated the clinical, pathologic, immunohistochemistry, and
surgical factors that contribute to ipsilateral breast tumor recurrence and locoregional recurrence. A Kaplan-
Meier analysis and Cox model were used to evaluate the main factors related to disease-free survival.
RESULTS: Of the 449 patients who received neoadjuvant chemotherapy, 98 underwent breast-conserving
surgery. The average diameter of the tumors was 5.3 cm, and 87.2% reached a size of up to 3 cm. Moreover,
86.7% were classified as clinical stage III, 74.5% had T3-T4 tumors, 80.5% had N1-N2 axilla, and 89.8% had
invasive ductal carcinoma. A pathologic complete response was observed in 27.6% of the tumors, and 100.0%
of samples had free margins. The 5-year actuarial overall survival rate was 81.2%, and the mean follow-up was
72.8 months. The rates of ipsilateral breast tumor recurrence and locoregional recurrence were 11.2% and
15.3%, respectively. Multifocal morphology response was the only factor related to ipsilateral breast tumor
recurrence disease-free survival (p=0.04). A multivariate analysis showed that the pathologic response
evaluation criteria in solid tumors (RECIST)-breast cutoff was the only factor related to locoregional recurrence
disease-free survival (p=0.01).
CONCLUSIONS: Breast-conserving surgery is a safe and effective therapy for selected locally advanced breast
tumors.
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Recurrence; Disease-Free Survival.
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’ INTRODUCTION
Breast cancer is the most common cancer among women.
Approximately 1.7 million new cases are estimated to occur
worldwide, and mortality is increasing in developing coun-
tries, primarily because the disease is not diagnosed until it is
in an advanced stage (1). In the past decade, advanced stage
III and IV carcinomas represented 8.5% of tumors in United
States and 44.7% of tumors in Brazil, making advanced carci-
noma a public health problem in the latter country (2).
From clinical, biological and pathologic perspectives,
locally advanced breast cancer (LABC) represents a relatively
heterogeneous group of tumors. Although neoadjuvant che-
motherapy (NC) does not increase the survival rates, it is
used to improve tumor resection, increase the rates of breast-
conservative surgery (BCS) (3, 4), and identify patients withDOI: 10.6061/clinics/2017(03)02
Copyright & 2017 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
134
CLINICAL SCIENCE
better prognoses, that is, patients who exhibit a pathologic
complete response (pCR) (5).
The rate of conservative surgery after NC varies from 37%
to 82% (6, 7); however, only 1.7% to 28% of these cases are
classified as LABC (7, 8). The role of conservative surgery in
the treatment of breast cancer is well established if the sur-
gery is combined with radiotherapy (5, 9). Studies of large
cohorts of patients with LABC who underwent NC and
conservative surgery are limited (10). The safety of BCS may
be assessed based on the rates of local and locoregional
recurrence (LRR). The selection of patients for BCS depends
on the tumor characteristics, pre- and post-chemotherapy
clinical-radiologic correlation, chemotherapy type, the mark-
ing and resection of the tumor bed, excision margins, the
type of response to chemotherapy, and the molecular sub-
type (11-14). Local recurrence and LRR are influenced by the
tumor characteristics, the size of the initial or residual tumor,
the rate of initial or residual lymph node metastatic disease,
the type of response to NC, the duration of follow-up, the
expression of markers measured by immunohistochemistry,
and the molecular subtype (11-15). However, studies of large
cohorts are necessary to assess the safety of BCS in patients
with LABC subjected to the same chemotherapy regimen.
These studies should evaluate the clinical, pathologic, and
molecular factors associated with ipsilateral breast tumor
recurrence (IBTR) and LRR.
’ MATERIALS AND METHODS
This study examined a retrospective observational cohort of
sequential patients with a clinical diagnosis of non-metastatic
LABC who had not undergone previous treatment but recei-
ved NC and BCS at an oncology tertiary hospital between
October 2005 and December 2012. LABC was defined as
patients with clinical stage III disease, i.e., advanced tumors at
diagnosis with tumors larger than 5 cm, clinical N2 metastasis,
clinical skin infiltration, or clinical ‘‘peau d’orange’’ at dia-
gnosis. Of the 449 patients subjected to NC, 98 received BCS
and were included in the study. Patients who underwent a
mastectomy were excluded from the analysis. Patients were
selected for BCS based on tumor size, breast-tumor relation,
clinical aspects, response to NC, radiological and post-NC
evaluation and surgeon expertise. T3 tumor selection was
based breast-tumor relation, associated with free surgical
margins. Only localized clinical T4 tumors were selected for
BCS. Inflammatory breast cancer was not selected for BCS.
Two patients who initially underwent BCS had intraoperative
positive margins and received a mastectomy. Thus, they were
excluded from the analysis. Table 1 presents the differences
between the groups of surgeries performed.
At the time of the observation, the standard NC regi-
men consisted of 4 cycles of AC (doxorubicin [adriamycin]
60 mg/m2 + cyclophosphamide 600 mg/m2), followed by
4 cycles or 12 cycles of T (Taxols [paclitaxel] 175 mg/m2 or
80 mg/m2, respectively). Standard Brazilian surgical treatment
consisted of quadrantectomy combined with level III axillary
lymph node dissection, and all patients were subjected to
whole-breast adjuvant radiotherapy (5040 cGy) combined with
a boost to the surgical bed (1000 cGy). They eventually also
received radiotherapy to the supraclavicular fossa. Axillary
radiotherapy was not performed. Five-year adjuvant hormonal
therapy was indicated for patients with estrogen/progesterone-
receptor (ER/PR)-positive tumors. No additional chemother-
apy was administered after surgery and was only indicated as
a palliative treatment in cases of recurrence. Neoadjuvant
trastuzumab was not administered, and adjuvant trastuzumab
was provided to some patients.
Clinical, surgical, and histological data as well as tumor
marker expression were assessed using immunohistochem-
istry; all data were standardized. For bilateral tumors, the
tumors exhibiting the most advanced stage were considered.
The tumor slides were assessed by pathologists (CSN and
LFAM), and pathologic characteristics were based on open
biopsy specimen at the time of diagnosis. The tumor, node,
metastasis (TNM) clinical staging system (7th edition, 2010)
was used. Prior to chemotherapy, clinical and radiologic
staging and systematic breast assessment were performed for
all patients. These clinical criteria were used to identify
LABC. If radiologic evaluation resulted in down-staging, the
patients were considered for analysis, but clinical-breast
radiologic evaluation defined the staging. The classification
of the morphologic response formulated by Chen et al. (11)
from MD Anderson Cancer Center (MDA) was used to clas-
sify the pathologic response to chemotherapy in the breast,
Table 1 - Main characteristics of the patients submitted to NC.
Variable Category BCS Mastectomy All group p
Tumor size cm 5.23 ± DP 1.64 7.15 ± DP 2.73 6.73 ± DP 2.64 o0.0001
Age at diagnosis years 48.48 ± DP 11.38 49.76 ± DP 10.55 49.5 ± DP 10.7 0.30
EC TNM II 13 (13.3%) 10 (2.9%) 23 (5.1%) o0.0001
III 85 (86.7%) 341 (97.1%) 426 (94.9%)
EC-T TNM T2 25 (25.5%) 18 (5.1%) 43 (9.6%)
T3 53 (54.1%) 178 (50.7%) 231 (51.4%) o0.001
T4 20 (20.4%) 155 (44.2%) 175 (3.9%)
EC-N TNM N0 17 (17.3%) 26 (7.4%) 43 (9.6%) 0.02
N1 56 (57.1%) 207 (59.0%) 263 (58.6%)
N2 22 (22.4%) 105 (29.9%) 127 (28.3%)
N3 3 (3.1%) 13 (3.7%) 16 (3.6%)
Molecular Luminal/ Her- 45 (45.9%) 158 (45.3%) 203 (45.4%) 0.02
Subtype* Luminal B/Her + 12 (12.2%) 93 (26.6%) 105 (23.5%)
Her 2+ 11 (11.2%) 41 (11.7%) 52 (11.6%)
Triple negative 30 (30.6%) 57 (16.3%) 87 (19.5%)
NC response Non pCR 71 (72.4%) 301 (85.8%) 372 (82.9%) o0.0001
pCR 27 (27.6%) 50 (14.2%) 77 (17.1%)
* cases with missing data
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which is based on the response of the solid mass, residual
multifocal disease, and no residual tumor (absence of tumor
and in situ carcinoma). Stable disease was added to this clas-
sification, and we considered it a morphologic classification.
The response evaluation criteria in solid tumors (RECIST)
radiologic classification cutoff values were adapted for 1-
dimensional pathologic breast assessment [(RECIST-breast
(RECIST-B)], with the cutoff points for 1-dimensional invasive
breast disease established as 30% for partial response and 10%
for progressive disease (16). A pCR was defined as the absence
of invasive disease in the breast and axilla.
Follow-up
The patients were selected based on clinical and radiologic
aspects before and after NC. The selected patients were sub-
jected to surgery, which was performed by a team compris-
ing 5 surgical oncologists and 1 breast cancer specialist. The
team’s preferential approach was the resection of the entire
disease area prior to NC (17). The planning was based on
tumor marking performed prior to NC, clinical assessment,
and radiologic assessment before and after NC. The frozen
section analyses were available during the surgeries. All
patients were assessed by multidisciplinary staff during the
postoperative period.
The patients were assessed every 6 months for 5 years, and
then once per year for an additional 5 years. The total follow-
up period was counted from the first visit to the last available
day. Breast clinical and radiological annual evaluations were
performed. In the presence of clinical signs, symptoms, or
proven recurrence, the patient was submitted for new radio-
logical staging. The time between the first evaluation to the
surgery was evaluated. Disease-free survival (DFS) was defi-
ned as the time elapsed from the performance of quad-
rantectomy to either the recurrence of disease or the last
follow-up visit. All patients who missed 2 scheduled visits
were considered lost to follow-up.
Endpoints
The response to chemotherapy, IBTR, and LRR were asses-
sed. IBTR was defined as a local relapse of breast cancer, even
in the case of secondary breast local invasion. LRR was defi-
ned as local relapse associated with ipsilateral regional lymph
node disease. Metachronous contralateral breast tumors were
not considered to be recurrences. In the presence of recurrence,
the patients were submitted to thoracic and abdominal tomog-
raphy associated with bone scintigraphy.
Molecular subtypes
Systematic assessment of samples in 10% neutral buffe-
red formalin blocks was performed using a tissue microarray
(TMA). The approximate molecular subtypes were assessed by
immunohistochemistry. The tumor markers anti-ER SP1, anti-
PR 1E2, anti-HER2/neu (clone 4B5), and anti-Ki-67 (clone 30-9)
were used (Roche Diagnostics). Tumors were rated ER/PR-
positive when nuclear labeling was evident in more than 1% of
tumor cells. A semi-quantitative score was used for HER2
staining. A score of 0, 1+, or 2+ was considered negative
staining, and a score of 3+ was considered positive staining.
Fluorescence in situ hybridization (FISH) was performed for
samples with a 2+ score. The approximate molecular subtypes
were clustered as a function of the immunohistochemical
results as follows: luminal A (ER/PR-positive, HER2-negative,
and Ki-67 o14), luminal B/HER-negative (ER/PR-positive,
HER2-negative, and Ki-67X14), luminal B/HER-positive (ER/
PR-positive and HER2-positive), HER2 (ER/PR-negative and
HER2-positive), and triple negative (ER/PR-negative and HER2-
negative). In the absence of TMA information, the primary
immunohistochemical lamina was reviewed. Discrepancies were
discussed until reaching consensus. To evaluate the analysis,
luminal A and luminal B/HER-negative samples were grouped
into the luminal/HER-negative group.
Statistical analysis
The data were collected, standardized, tabulated, and
analyzed using the SPSS 20.0 software for Macs (Armonk,
New York, NY). Univariate analyses of the categorical var-
iables related to local and locoregional DFS were performed
using the Kaplan-Meier method. The difference between the
curves was assessed with the log-rank method. A Cox model
was used to identify variables independently associated with
local and locoregional DFS. We evaluated continuous vari-
ables without dichotomization. For Cox modeling, we evalua-
ted categorical interest variables and variables exhibiting
po0.10 in the univariate analysis. An exploratory model was
used for Cox multivariate analyses. The significance level was
set to po0.05.
Ethics
The study was approved by the Research Ethics Commit-
tee, no. 135/2008.
STROBE statement
This study adhered to the STROBE guidelines for cohort
studies.
’ RESULTS
Ninety-eight patients with LABC who had undergone NC
and BCS were evaluated. Tumor size, clinical TNM stage, pT-
TNM, and pN-TNM were lower, whereas the incidence of
triple-negative tumors was higher in the BCS group than the
mastectomy group; age did not significantly differ between
these groups (Table 1). The average age of patients who had
undergone BCS was 48.5 years old, and the average duration
of complaint was 8 months. Bilateral tumors were identified
in 2% of samples. The average diameter of the tumors was
5.3 cm (2 to 8.5 cm). Clinical-radiologic staging was performed
for all patients, but 4 patients (4.2%) were classified as stage IIa
(T2N0) after initial radiologic examination and were further
analyzed. Bone scintigraphy was performed for all patients. In
58.2% of patients, staging was based on chest radiographs and
abdominal ultrasound, whereas it was based on thoracic and
abdominal computed tomography in the remaining patients.
All patients underwent mammography with breast ultrasound
(64.3%) or ultrasound and magnetic resonance imaging (MRI)
(23.5%). Lesions were preoperatively marked on the skin in
23.5% patients. The main characteristics related to tumor
staging and treatment are described in Table 2.
Chemotherapy treatment included the 4AC+4T (81.6%)
and 4AC+12T (11.2%) regimens, and the standard regimen
was modified in 7.1% of patients because of toxicity (4.1%) or
disease progression (3.1%).
Surgery
Surgery was performed 43 days after the end of che-
motherapy, on average. The average duration from the first
visit to surgery was 8.3 months. All patients underwent a
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quadrantectomy, and oncoplastic surgery was performed
in 26.5% of patients, which was distributed as follows: cen-
tral quadrantectomy (8.1%), rotation flap (7.1%), periareolar
(5.1%), inferior pedicle (4.1%), and superior pedicle (2.0%).
Level III axillary lymph node dissection was performed in
97.0% of patients, the sentinel lymph node was investigated
in 2.0% of patients, and no axillary approach was employed
in 1.0% of patients.
The margins were tumor-free in all patients, and 81.6% of
patients harbored tumors measuring 12.3 mm (1 to 40 mm)
on average. Moreover, 13.3% of patients had pCR, and the
margins were not evaluated. In 5.1% of patients (5), the
margins were considered free, and the distance measure-
ment was not evaluated. The average weight of the surgi-
cal specimens was 233 g (41.5 to 980 g). The average number
of dissected lymph nodes reported during pathologic
evaluation was 18.5 (4 to 42). Table 3 presents the response
to NC.
Adjuvant treatment
With regard to adjuvant therapy, 98% of patients received
radiotherapy to the chest wall (5040 cGy) and a boost to the
breast (1000 cGy) near the incision. Radiotherapy to the sup-
raclavicular fossa was performed in 89.4% of patients. Two
patients did not receive radiotherapy, 1 because of rapid
disease progression and the other refused because of clau-
strophobia. Hormonal therapy was administered to 57.1% of
patients and consisted of tamoxifen alone, anastrozole alone,
or a combined regimen in 35.7%, 3%, and 18.4% of patients,
respectively. Adjuvant trastuzumab was administered to
only 2.0% of patients.
Follow-up
The average duration of follow-up was 64.1 months (13.4
to 105.7 months), with the follow-up period decreasing to
55.8 months (3.6 to 95.7 months) after surgery. After the
exclusion of deaths due to disease, the average total duration
Table 2 - Univariate analysis of factors related to local and locoregional recurrence -free survival.
Category Variable n (%) Local p Locoregional p
60 months DFS 60 months DFS
Pre-operative
EC TNM II 13 (13.3) 77.1 0.54 67.5 0.37
III 85 (86.7) 89.5 82.8
ECT - TNM T2 25 (25.5) 78.6 0.53 66.8 0.23
T3 53 (54.1) 89.2 85.6
T4 20 (21.4) 95.0 95.0
ECN - TNM N0 17 (17.3) 100.0 0.71 100.0 0.40
N1 56 (57.1) 85.2 81.0
N2-3 25 (25.5) 87.2 77.8
Tumor marking Absent 75 (76.5) 86.0 0.68 79.9 0.37
Present 23 (23.5) 95.0 95.0
Histologic type CDI 90 (89.8) 89.5 0.13 84.1 0.31
CLI+ other 8 (8.2) 70.0 70.0
Nottinghan grade* G1+2 56 (56.4) 85.1 0.29 76.4 0.07
G3 40 (41.7) 91.2 91.2
Necrosis* Absent 60 (61.2) 81.9 0.039 73.7 0.008
Present 36 (37.5) 97.1 97.1
Peritumoral Slight 56 (57.2) 89.9 0.80 85.2 0.68
Infiltration* Moderate/intense 10 (40.8) 85.0 79.4
Lymphatic Absent 85 (88.5) 86.6 0.29 82.1 0.75
embolization* Present 11 (11.5) 100.0 90.9
ER Negative 45 (45.9) 86.9 0.50 82.7 0.90
Positive 53 (54.1) 88.9 83.4
PR Negative 52 (53.1) 88.6 0.80 86.7 0.49
Positive 46 (46.9) 86.9 78.8
Her2 Positive 23 (23.5) 86.1 0.79 80.0 0.41
Negative 75 (76.5) 88.8 89.0
Molecular Luminal / Her - 45 (45.9) 85.5 0.63 79.0 0.40
Subtype Luminal B Her+ 12 (12.2) 91.7 91.7
Her2 11 (11.2) 78.8 79.0
Triple negative 30 (30.6) 93.2 89.8
Postoperative
Oncoplastic Absent 72 (73.5) 85.0 0.50 79.7 0.52
surgery Present 26 (26.5) 96.0 92.0
RECIST-B Complete response 31 (31.6) 92.6 0.16 92.7 0.003
Partial response 64 (64.3) 86.9 80.6
Stable disease 3 (3.1) 66.7 33.3
Morphology Solid mass 50 (51.0) 89.9 0.04 82.7 0.03
MDA (11) Multifocal disease 13 (13.3) 77.3 69.5
Without disease 31 (31.6) 92.0 92.1
Stable disease 4 (4.1) 75.0 50.0
pCR/ NSABP Absent 71 (72.4) 87.3 0.58 80.6 0.28
Present 27 (27.6) 90.4 90.4
DFS = disease free survival; pCR = pathologic complete response;
* 2 cases missing data
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of follow-up was 72.8 months (34.4 to 105.7 months) and
64.1 months (26.3 to 95.9 months) after surgery. Moreover,
6.1% of patients (6) were considered lost of follow-up, and
5/6 patients exhibited DFS with a mean time of 39.4 months
(26.3-48.6 months).
By the end of the follow-up period, 19.5% of the patients
had died from breast cancer, 5.1% had died from other
causes, 7.1% were living with cancer, and 68.4% were alive
and free of disease. The main sites of metastases were in
the bones (16.3%), lungs (13.3%), liver (8.2%), and brain
(4.1%). The overall actuarial survival (OS) rates at 36, 60, and
96 months were 87.7%, 81.2%, and 71.4%, respectively
(Figure 1).
Recurrence
The average months after surgery for recurrence vary from
1.8 to 81.3 months and was 26.4, 26.8 and 27.1 months in
general, IBTR and LRR, respectively. At 36 months 72.4% of
the general recurrence occurred, 83.3% of the IBTR and 76.5%
of the LRR. The overall DFS rates at 36, 60 and 96 months
were 77.9%, 68.9% and 67.0%, respectively (Figure 1).
The IBTR rate was 11.2%. IBTR was classified as local
recurrence associated with systemic disease (3.1%), local plus
LRR (3.1%), breast recurrence alone (3.1%), and secondary
breast invasion from sternal recurrence (2.0%). When asses-
sing disease progression, some patients exhibited rapidly
progressive disease with early local recurrence plus LRR
(2.0%), sternal recurrence extending to the breast (2.0%),
breast recurrence alone (3.1%), and multiple local recurrence
plus LRR (4.1%). Excluding the instance of local sternal
recurrence that infiltrated the breast, the primary recurrence
rate was 9.3%.
A univariate analysis of local DFS relative to the
categorical variables (Table 1) showed that the absence of
necrosis (p=0.04) and the morphologic response to che-
motherapy characterized by multifocal disease and stable
disease were associated with poorer survival (p=0.04).
Neither age [p=0.33, risk ratio 1.01, confidence interval (CI)
0.99-1.03] nor initial tumor size (p=0.35, risk ratio 1.06, CI
0.93-1.20) influenced IBTR DFS. The Cox univariate analysis,
which was used to explore factors possibly related to IBTR
DFS (Table 2), showed that multifocal morphology was the
only factor associated with IBTR because it increased the
IBTR 5.97-fold (p=0.04). Figure 1 shows the overall and
morphology factor risk curves related to the hazard risk of
local DFS.
The LRR rate was 15.3% and was distributed as follows:
ipsilateral supraclavicular fossa (4.0%), ipsilateral axilla
(3.1%), local and systemic recurrence (3.1%), breast recur-
rence alone (3.1%), and breast associated with sternal recur-
rence (2.0%).
A univariate analysis of the categorical variables relative to
locoregional DFS (Table 1) showed that the pathologic
RECIST-B response (p=0.003), necrosis (p=0.008), and mor-
phology were related to locoregional DFS. Neither age
(p=0.41, risk ratio 1.00, CI 0.98-1.03) nor initial tumor size
(p=0.27, risk ratio 1.08, CI 0.94-1.23) influenced LRR DFS.
The Cox univariate analysis showed that the absence of
tumor necrosis at diagnosis increased the LRR 9.33-fold
(p=0.03), multifocal morphology increased the risk of LRR
6.09-fold (p=0.04), and stable disease increased the risk of
LRR 9.08-fold (p=0.03). However, the RECIST-B pathologic
response was the main factor related to locoregional DFS
(p=0.01) because stable RECIST-B disease increased the
risk of LRR 16.93-fold (p=0.005). An exploratory Cox multi-
variate analysis model showed that RECIST-B pathologic
response was the only factor related to locoregional DFS.
Figure 2 shows the curves related to the hazard risk of
locoregional DFS.
’ DISCUSSION
NC provides global survival similar to adjuvant che-
motherapy, with the added advantage of identifying patients
with better prognoses, that is, patients who exhibit pCR in
addition to increasing the rates of BTC (18). The primary
indication for NC is larger tumors or tumors with higher
rates of lymph node involvement. When comparing patients
treated with NC and BCS with patients subjected to mas-
tectomy, the former have a lower T-TNM stage at diagnosis;
higher rates of pCR; and higher rates of ER-negative, PR-
negative, and triple-negative tumors, indicating bias in the
Table 3 - Cox analysis of factors related to local and locoregional recurrence-free survival.
Variable Category OR CI p factor p general
Local recurrence (IBTR)
Necrosis Present 1.00 Ref 0.07
Absent 7.00 0.85-57.19 -
Morphology Without disease 1.00 Ref. 0.08
MDA (11) Solid mass 1.28 0.23-6.98 0.78
Stable disease 4.60 0.42-50.79 0.21
Multifocal disease 5.97 1.09-32.70 0.04
Locoregional recurrence (LRR)
RECIST-B Complete response 1.00 Ref. 0.01
Partial response 2.85 0.63-12.85 0.17
Stable disease 16.93 2.37-120.84 0.005
Necrosis Present 1.00 Ref. 0.03
Absent 9.33 1.23-71.03 -
Morphology Without disease 1.00 Ref. 0.06
MDA (11) Solid mass 2.25 0.47-10.86 0.31
Multifocal disease 6.09 1.11-33.40 0.04
Stable disease 9.08 1.28-64.51 0.03
Nottinghan G1+2 1.00 Ref. 0.08
grade G3 0.33 0.09-1.16 -
OR = odds ratio; CI = confidence interval; Ref. = Reference
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analysis of this subgroup. This bias may influence the rates of
recurrence and survival (19). In our group of patients,
patients who underwent BCS exhibited better survival than
the mastectomy group (p=0.002), which corroborated pre-
vious reports. Bias selection likely occurred based on tumor
size, breast-tumor relation, response to NC, and molecular
subtype (Table 1) because BCS was performed in patients
with smaller tumors, lower clinical TNM stage, and a better
response to NC. Because the characteristics differed between
groups, we only evaluated patients who underwent BCS.
Bleicher et al. evaluated Surveillance, Epidemiology, and End
Results (SEER) data from a cohort of 5,685 patients aged466
years old with tumors45 cm. Of these patients, 887 (15.6%)
underwent BCS, and only 205 (3.6%) received NC. BCS was
associated with a lower clinical stage and more NC, but only
101 patients received both NC and BCS, and these patients
were not evaluated separately (20). Our study represents one
of the largest institutional retrospective cohort studies of
LABC treated with NC and BCS (11).
BCS is safe provided that the excision margins are free of
disease and this treatment is combined with adjuvant radio-
therapy to the breast (21, 22). BCS was initially used to treat
tumors smaller than 3 cm associated with a 1-cm free margin.
These criteria are changing, and smaller margins are currently
accepted (23). A meta-analysis of randomized controlled trials
showed that BCS is a safe treatment for patients with clinical
stage I and II disease and tumors smaller than 5 cm (24). SEER
data evaluated for tumors45 cm indicated that breast cancer-
specific survival did not differ between patients who received
BCS and patients who underwent a mastectomy, but the
women in this study were older, the IBTR and molecular
subtype were not evaluated, and few patients received NC (20).
The rate of conservative surgery after NC varies from 37%
to 82% (6, 7); however, only 1.7% to 28% of patients exhibit
LABC (7, 8). The LABC candidates who were initially
selected were patients without skin or chest wall involve-
ment and who were free of multicentric disease or extensive
microcalcifications. They harbored tumors smaller than 5 cm,
exhibited favorable tumor localization, had no contraindica-
tions for radiotherapy, and had negative margins. Primary
inflammatory carcinoma is a contraindication for BCS (25).
Patients with N2-3 lymph nodes, residual tumors 42 cm,
residual multifocal components, and the presence of lym-
phovascular embolization should be cautiously assessed
because of the higher risk of IBTR (11, 26). Therefore, the
cutaneous infiltration criteria have become more flexible
Figure 1 - OS of patients with NC and BCS (upper images) and hazard risk of local recurrence DFS (lower images).
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for localized cutaneous infiltration and the breast/tumor
volume ratio, and the initial indications for oncoplastic
surgery have been expanded (17). Although the average
size of the initial tumors was 5.3 cm (varying from 2 to
8.5 cm) in the present cohort, the margins were disease-
free in 100% of cases, with a distance to the tumor of
12.3 mm. In addition, oncoplastic techniques were used in
26.5% of patients, which supports the use of BCS in selected
cases of LABC.
The preoperative planning was based on clinical-radiolo-
gic data and operative freezing. Two patients were excluded
from the cohort because of positive surgical margins, which
resulted in conversion to mastectomy.
Diagnostic imaging tests are essential to pretreatment
therapeutic planning (3) and were performed before and
after the administration of NC in 100% and 87.7% of patients,
respectively. Although not shown numerically, a tendency
toward the resection of the entire tumor bed before NC was
observed in this study. Not all patients who exhibited a com-
plete clinical response (21) reached pCR, and the anatomic-
pathologic assessment is not always uniform. In this regard,
the ‘‘Residual Cancer Burden’’ method renders the resection
of the full area necessary prior to NC (27), but it is used in
prospective studies. Pathologic sampling interferes with the
pathologic results. In the present study, the average number of
blocks per surgical specimen was 20, but a consensus for
pathologic evaluation was obtained in 2015 (28).
Upon the assessment of patients subjected to BCS and
radiotherapy, we should consider studies of patients who did
not receive NC that demonstrate the long-term safety of BCS.
For example, Veronesi (9) assessed tumors smaller than 2 cm
and identified a recurrence rate of 8% at 20 years, whereas
Fisher (NSAPB-B06), who assessed tumors smaller than
4 cm, reported recurrence rates at 20 years of 14.3% for patients
who underwent lumpectomy and breast radiation and 39.2%
for patients who did not receive radiation (21). In patients
subjected to NC and BCS, this rate was reported to be 14% at
5.8 years (29), 19% at 4.6 years (15), and 21.5% at 20 years
(30); however, the assessed tumors differed diagnostically
and in their initial staging (19). Therefore, the possibility
of new surgical margins remains open for discussion, but
case-control studies assessing locally advanced tumors are
lacking. NSABP B-27, which assessed patients with T1c-3N0
or T1-3N1M0 disease, was designed to evaluate the addition
of taxanes to anthracyclines and reported an average tumor
size of 4.4 cm and a 6% IBTR rate at 102 months; however,
Figure 2 - Hazard risk curves of locoregional DFS.
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only 30% of cases exhibited lymph node involvement. In the
present cohort, the average tumor size was 5.3 cm, and 87.2%
of tumors were larger than 3 cm; 88.9% of patients were
diagnosed with stage III disease, 74.5% of patients harbored
stage T3-4 disease, and 82.6% of patients had stage N1-3
disease. The IBTR rate was 11.2% at 64.1 months. Although
this rate is high, it is lower than the rate reported in a study
by Fisher of patients subjected exclusively to lumpectomy
without radiotherapy (21). These findings demonstrate the
effectiveness of BCS in patients with LABC subjected to NC
and adjuvant radiotherapy.
In the assessment of IBTR, we must discriminate true
recurrence at the surgical site, ipsilateral second primary
tumors, and ipsilateral thoracic wall tumors (31). Although
ipsilateral thoracic wall events involving the sternal bone
were defined as a distant event in 2014 (31), previous studies
with long follow-up period did not specify this form of
recurrence (32). In the present study, we observed 2 patients
with simultaneous IBTR and sternal infiltration, but 1 patient
underwent local full-thickness chest wall resection. We opted to
consider this case as local recurrence to better compare our
results to those of other studies with long follow-up periods. No
pattern is associated with the type of local recurrence, but many
recurrences are defined as multiple recurrence. Alternatively,
recurring tumors may indicate resistance to treatment and
subsequent multiple recurrences. In the present study, the LRR
rate was 15.3% and consisted of all patients with local recur-
rence and the 4 patients with locoregional lymph node involve-
ment. This finding corroborates the analysis of the DFS results.
The chi-squared test may be used to calculate recurrence,
but we also assessed DFS because recurrence depends on
time. Several factors are associated with IBTR and LRR.
Better results were observed in patients who showed an
early response to treatment (33) and were positive for hor-
monal receptors (12); poorer outcomes were reported for
patients with lymphovascular invasion(11), residual tumors
larger than 2 cm (11), multifocal disease after chemotherapy
(11, 34), no expression of hormonal receptors, stage III and
N2-3 axillary nodal status (15), age p40 years old, excision
margins p2 mm, and S-phase fraction 44% (30).
Few studies have examined a sufficient number of cases to
assess the rates of recurrence in patients subjected to NC and
BTC (11, 33, 34). In the present study, which evaluated a large
sample over a long follow-up period, the morphologic res-
ponse, although valid, was not significantly associated with
recurrence, whereas the RECIST-B response was shown to have
prognostic value in a multivariate analysis. The response to
NC can be classified into several categories (35). Chen et al.
suggested a morphologic classification of the response, show-
ing that the response correlates with the occurrence of IBTR
(11). In the present study, morphologic assessment showed an
association, albeit a non-significant one, between the presence
of multifocal disease/stable disease and higher rates of IBTR
and LRR. The RECIST-B pathologic response (p=0.02) was the
only variable retained in the multivariate model related to LRR:
the risk was 2.85 times higher among patients with a partial
response (p=0.17) and 16.93 times higher among patients with
stable disease (p=0005).
In the present cohort, the absence of necrosis in the
pretreatment biopsy sample was the only histological factor
that was associated with IBTR and LRR. This finding is
corroborated by other studies, which detected an association
between complete response and the presence of necrosis (36).
The absence of necrosis was associated with a 7.00-fold higher
rate of IBTR, but this increase was not significant (p=0.07). It
was also associated with a 9.33-fold higher rate of LRR (p=0.03)
in univariate analysis. The only significant factor related do
LRR in multivariate analysis was the RECIST-B response.
In the assessment of IBTR, other variables, such as the type
of tumor fragmentation and the presence of surgical margins,
should also be considered. Thus, the rates of IBTR were
reported to be 12.7% and 20.3% in the presence and absence
of tumor-free margins, respectively (30). In the present study,
all patients exhibited tumor-free margins. In a previous
study, the presence of multifocal disease increased the risk of
IBTR 3.3-fold (12), which is corroborated by this study:
multifocal disease increased the rate of IBTR 5.97-fold
(p=0.04). In addition, the molecular subtypes are related to
the rate of recurrence in an adjuvant (37) and neoadjuvant
setting (38). Specifically, the rates of recurrence were 0.8% for
luminal tumors (ER/PR-positive and HER2-negative), 1.5%
for luminal B tumors (ER/PR-positive and HER2-positive),
8.4% for HER2 tumors (ER/PR-negative and HER2 positive),
and 7.1% for triple-negative tumors.
A possible limitation of the present study is the retro-
spective and nonrandomized design in which cases were
selected in a continuous manner, that is, based on the
feasibility of BCS. Thus, multiple elements influenced the
selection of patients, including age, comorbidities, breast-
volume ratio, and response to NC. Another limitation of this
study is the absence of NC association with trastuzumab,
which may affect the pCR, OS, and DFS (39). Because HER2
tumors represent 23.5% (29) of patients, we observed only 3
incidences of local recurrence/LRR in this group and a 0.487-
fold reduction in the recurrence rate (39). The addition of
trastuzumab would slightly decrease the overall recurrence
rate, but this drug was not used by the Brazilian Public
Health System at the time of NC treatment.
The present study corroborates the fact that in cases
selected by clinical and radiologic findings with a satisfac-
tory response to NC, BCS is feasible and safe for the treat-
ment of locally advanced tumors, provided that the tumor is
completely resected, surgical margins are clear, and patients
are subjected to complementary multimodal treatment. This
finding was corroborated by the occurrence of acceptable
rates of local recurrence and LRR.
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